Important note: Information in this article was accurate in March 2000. The state of the art may have changed since the publication date.
Treatment Issues: Newsletter of Experimental AIDS Therapies - Volume 14, Number 3/4, Spring 2000
Nelfinavir (Viracept), Agouron's protease inhibitor that was initially approved at a dose of 750 mg (three 250 mg tablets) three times each day, has become easier to take. Late in 1999, the FDA approved a dose of 1250 mg (five 250 mg tablets) twice daily. The change was based on a clinical trial comparing the two doses of nelfinavir plus d4T and 3TC. Both arms had similar decreases in viral load and increases in CD4 counts, as well as similar rates of diarrhea (14 to 18 percent), a common side effect of nelfinavir.
Agouron has also announced that the FDA approved a film-coated nelfinavir tablet. Previously, there were problems with the tablets breaking, sometimes while being swallowed. The new coating should make the tablet easier to take.
20000310
GM140310
Copyright © 2000 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org
ÆGiS is made possible through unrestricted grants from Roxane Laboratories, Inc., iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.